LTBR and systemic sclerosis: Current therapeutics are limited in other inflammatory and fibrotic diseases, such as IPF and SSc/scleroderma; thus, interrogation of LIGHT, HVEM, and/or LTβR biomarkers will undoubtedly be important in identifying appropriate patients.